Program
vonaprument
Also written as “ANX007”, “Vonaprument” and “2.5mg ANX007”.
Its studies are mostly in Geographic Atrophy · Glaucoma, Open-Angle, led by Annexon.
Furthest: phase 3, since Jul 15, 20245 company-led studies, 2 open or runningNext primary completion: Jul 31, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Annexon | 52 open or running | phase 3since Jul 15, 2024 | Mar 28, 2018 | Jul 31, 2027phase 3 · NCT06510816 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2018First study: phase 1 study in Glaucoma, Open-AngleFirst studyNCT03488550 · 9 enrolled · United States
- Dec 13, 2018Phase 1 study in Glaucoma, Open-AngleNCT04188015 · 17 enrolled · United States
- Dec 1, 2020Phase 2 study in Geographic AtrophyNCT04656561 · 270 enrolled · United States, Australia, New Zealand
- Jul 15, 2024Phase 3 study in Geographic AtrophyNCT06510816 · 659 enrolled · United States, Australia, Austria and more
- Sep 3, 2026Phase 3 study in Geographic AtrophyNCT07807969 · 605 planned · United States
Ahead
- Jul 31, 2027Primary completion: phase 3 study in Geographic AtrophyNCT06510816
- Jul 31, 2029Primary completion: phase 3 study in Geographic AtrophyNCT07807969
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07807969Geographic Atrophy · United States | 3 | Not yet recruiting | Jul 31, 2029 | 605 |
| NCT06510816Geographic Atrophy · United States, Australia, Austria and more | 3 | Active, not recruiting | Jul 31, 2027 | 659 |
| NCT04656561Geographic Atrophy · United States, Australia, New Zealand | 2 | Completed | Mar 28, 2023 | 270 |
| NCT04188015Glaucoma, Open-Angle · United States | 1 | Completed | Jun 3, 2019 | 17 |
| NCT03488550Glaucoma, Open-Angle · United States | 1 | Completed | Aug 3, 2018 | 9 |
How it is read
Names in the registry
- “ANX007”, 2 entries
- “Vonaprument”, 2 entries
- “2.5mg ANX007”, 1 entry
- “5.0mg ANX007”, 1 entry
Conditions, from the studies’ own filings
- Geographic Atrophy, 3 studies
- Glaucoma, Open-Angle, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.